As compared with standard second line docetaxel chemotherapy, the advanced stage NSCLC patients receiving PD-1/PD-L1 antibodies showed significant increase in the incidence rate of grade 1-4 adverse events (AEs). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.